Ultragenyx Pharmaceutical Inc

Lezárt

SzektorEgészségügy

32.79 -4.18

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

30.35

Maximum

34.94

Fő mutatók

By Trading Economics

Bevétel

-56M

-185M

Értékesítés

-71M

136M

Egy részvényre jutó nyereség

-1.54

Profit margin

-136.029

Munkavállalók

1,371

EBITDA

-50M

-155M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+75.33% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. aug. 4.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

420M

2.9B

Előző nyitás

36.97

Előző zárás

32.79

Ultragenyx Pharmaceutical Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. jún. 30. 23:21 UTC

News
Social Media

Micron Technology shares rose after hours, buoyed by a $250 million investment and significant revenue growth linked to AI chipmakers.

2026. jún. 30. 23:11 UTC

News

Comcast Corp shares rose in after-market trading, continuing an upward trend. The company's market cap now exceeds that of American Tower, ranking 135th in the S&P 500.

2026. jún. 30. 23:06 UTC

News
Correlated Moves

The US 10Y Treasury Bond Index is near unchanged in after-market hours, following a slight increase earlier in the day. The iShares 7-10 Year Treasury Bond ETF mirrors this stability.

2026. jún. 30. 23:06 UTC

Social Media
News

Microsoft shares rise in after-market hours, driven by strength in the Systems Software sub-sector and a new partnership with Chevron for a natural gas facility.

2026. jún. 30. 23:02 UTC

Social Media
News

Tesla Inc. shares are lower in after-market hours following Michael Burry's short position disclosure and a fatal incident involving one of its vehicles.

2026. jún. 30. 23:02 UTC

News

The iShares 20+ Year Treasury Bond ETF is lower in after-market trading, reflecting broader declines in U.S. indices and mixed market conditions.

2026. jún. 30. 23:02 UTC

News
ETF Constituents

Vanguard Growth ETF declines in after-market trading, driven by losses in top holdings NVIDIA, Tesla, and Meta, despite slight gains in the Nasdaq 100 Index.

2026. jún. 30. 23:01 UTC

News

Fox Corp has secured a $1 billion loan to fund its Roku acquisition. Shares are higher in after-market hours, aided by a strong Broadcasting sector.

2026. jún. 30. 22:51 UTC

News

Vanguard Total Bond Market ETF is lower in after-market hours, reflecting broader market pullbacks amid geopolitical tensions and fluctuating oil prices.

2026. jún. 30. 22:31 UTC

News
ETF Constituents

The Vanguard Information Technology ETF is lower in after-market hours, impacted by declines in key holdings AMD and Intel amid cautious investor sentiment.

2026. jún. 30. 22:26 UTC

News
Correlated Moves

iShares iBoxx $ Investment Grade Corporate Bond ETF declines in after-hours trading amid broader market losses and concerns over Bank of Japan's Tankan Survey results.

2026. jún. 30. 20:08 UTC

News
Correlated Moves

Ethereum is trading lower, influenced by Bitcoin's decline. Sharplink's acquisition of 10,000 ETH at $1,611 has not prevented the drop.

2026. jún. 30. 20:07 UTC

News

Vertex Pharmaceuticals is trading lower amid broader market pressures despite promising first-quarter results. Earlier in the session, shares briefly reached a high before declining.

2026. jún. 30. 20:07 UTC

Social Media
News

Intel Corp shares are advancing, driven by bullish semiconductor activity and increased buying interest. The stock reached a post-alert high of $131.14.

2026. jún. 30. 20:07 UTC

News
Correlated Moves
Social Media

NVIDIA shares rose following SemiAnalysis's bullish projection for data center revenue, expected to exceed consensus by 20% in fiscal 2027's second half.

2026. jún. 30. 20:07 UTC

News
Correlated Moves

Ethereum is trading lower, influenced by Bitcoin's decline and broader market pressures. Earlier, it dipped to a session low of $1,611.

2026. jún. 30. 20:03 UTC

News
Correlated Moves
Social Media

Apple Inc. shares are higher after the Supreme Court agreed to hear its appeal in the Epic Games antitrust case, potentially benefiting App Store fees.

2026. jún. 30. 20:03 UTC

News
Correlated Moves
Social Media

Analyst raises AMD price target to $615, citing strong AI demand. Shares are trading higher since Monday, reflecting positive market sentiment.

2026. jún. 30. 20:03 UTC

Social Media
Correlated Moves
ETF Constituents
News

Invesco QQQ Trust Series I advances today, driven by positive technology sector sentiment and strong performance from major contributors like AMD and Apple.

2026. jún. 30. 20:03 UTC

News
ETF Constituents

Health Care Select Sector SPDR Fund declines as health care underperforms, with Eli Lilly and Stryker contributing to the negative performance during Tuesday's session.

2026. jún. 30. 20:03 UTC

Correlated Moves
News
ETF Constituents

Germany's retail sales rose 1.1% in May, exceeding expectations. The iShares MSCI Germany ETF is gaining, supported by strong performances from key holdings.

2026. jún. 30. 20:02 UTC

Correlated Moves
Social Media
News

Applied Materials shares are higher today following price target increases, including Susquehanna's raise to $900 from $575, reflecting strong analyst sentiment.

2026. jún. 30. 20:01 UTC

News

Expedia Group Inc shares are lower today amid a decline in the Hotels, Resorts & Cruise Lines sector. Wells Fargo cut its price target to $303.

2026. jún. 30. 20:01 UTC

News

ASML Holding NV shares are higher amid positive sentiment and Bernstein's price target increase, supported by $518 billion in semiconductor infrastructure investments.

2026. jún. 30. 20:01 UTC

News
Correlated Moves

Intuitive Surgical shares are lower, reaching a four-week low amid declines in the Health Care Equipment sub-sector and volatility in the market.

2026. jún. 30. 20:01 UTC

News
Social Media

Illumina Inc shares are lower as Roche launches a competing gene sequencer at a lower price, challenging Illumina's market share in genetic testing technology.

2026. jún. 30. 19:56 UTC

News

Henry Schein announced a partnership with GoTu Technology to enhance dental workforce support, though shares are lower during Tuesday's session.

2026. jún. 30. 19:56 UTC

News
Correlated Moves

Concerns over currency volatility arise as the yen weakens against the dollar. EUR/HKD remains roughly flat since Monday's close amid broader market dynamics.

2026. jún. 30. 19:52 UTC

News

Costco Wholesale shares are lower, reaching a four-week low of $938.50, amid declines in the Consumer Staples Merchandise Retail sub-sector.

2026. jún. 30. 19:52 UTC

News

Align Technology Inc shares are declining amid a formal antitrust investigation by the European Commission into its practices related to iTero scanners and Invisalign aligners.

Társak összehasonlítása

Árváltozás

Ultragenyx Pharmaceutical Inc Előrejelzés

Célár

By TipRanks

75.33% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 53.79 USD  75.33%

Magas 96 USD

Alacsony 26 USD

15 Wall Street elemző 12 hónapos célárain alapulva a(z)Ultragenyx Pharmaceutical Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

15 ratings

14

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
help-icon Live chat